Topic

Virginia

A collection of 501 issues

How to Get Naglazyme (galsulfase) Covered by Blue Cross Blue Shield in Virginia: Complete Prior Authorization Guide

Answer Box: Getting Naglazyme Covered by Blue Cross Blue Shield in Virginia Blue Cross Blue Shield Virginia requires prior authorization for Naglazyme (galsulfase), with coverage based on confirmed MPS VI diagnosis, documented functional impairment, and objective outcome measures. The fastest path to approval involves submitting comprehensive documentation through Anthem'

How to Get Darzalex / Darzalex Faspro (daratumumab) Covered by Aetna (CVS Health) in Virginia: Complete Guide to Prior Authorization, Appeals, and State Protections

Answer Box: Your Fastest Path to Coverage Getting Darzalex / Darzalex Faspro (daratumumab) covered by Aetna (CVS Health) in Virginia requires prior authorization and often step therapy compliance. Your oncologist must document that bortezomib (the preferred agent) has failed or is contraindicated. Submit Aetna's precertification form via phone (1-866-752-7021)

Work With Your Doctor to Get Keppra (Levetiracetam) Approved by UnitedHealthcare in Virginia: Complete Provider Collaboration Guide

Answer Box: Getting Keppra Covered by UnitedHealthcare in Virginia Generic levetiracetam typically requires no prior authorization from UnitedHealthcare, but brand-name Keppra often does. The fastest path to approval: 1) Ask your doctor to prescribe generic levetiracetam first (usually covered), 2) If brand Keppra is medically necessary, document a 4-week generic

How to Get Tremfya (Guselkumab) Covered by Cigna in Virginia: PA Forms, Appeals, and Approval Timeline

Quick Answer: Getting Tremfya (Guselkumab) Covered by Cigna in Virginia Tremfya requires prior authorization from Cigna and is typically placed on Tier 5 (specialty) with step therapy requirements. To get coverage in Virginia: 1) Have your doctor submit the Cigna PA form with TB screening, PASI scores, and documented failure

How to Get Sylvant (Siltuximab) Covered by Humana in Virginia: Coding, Appeals, and State Review Process

Answer Box: Getting Sylvant Covered by Humana in Virginia Sylvant (siltuximab) requires prior authorization from Humana for idiopathic multicentric Castleman disease (iMCD). Use ICD-10 code D47.Z2 and HCPCS J-code J2860 (10 mg units). Submit PA requests through Humana's provider portal with HIV/HHV-8 negative test results and

How to Get Orfadin (nitisinone) Covered by UnitedHealthcare in Virginia: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Orfadin Approved by UnitedHealthcare in Virginia UnitedHealthcare requires prior authorization for Orfadin (nitisinone) but does not require step therapy since it's the only FDA-approved treatment for hereditary tyrosinemia type 1 (HT-1). To get approval in Virginia: (1) Gather complete HT-1 diagnosis documentation including elevated succinylacetone

How to Get Enhertu (fam-trastuzumab deruxtecan-nxki) Covered by Blue Cross Blue Shield in Virginia: Appeals, Forms & Timeline

Quick Answer: Your Path to Enhertu Coverage in Virginia Enhertu (fam-trastuzumab deruxtecan-nxki) requires prior authorization from Blue Cross Blue Shield Virginia, typically placed on specialty tier 4 formularies. Your oncologist must submit HER2 testing results, prior treatment documentation, and clinical justification. If denied, Virginia's external review process through

How to Get Humira (adalimumab) Covered by Aetna CVS Health in Virginia: Appeals Guide with Forms & Timelines

Quick Answer: To get Humira (adalimumab) covered by Aetna CVS Health in Virginia, you'll likely need prior authorization with documented step therapy failures. If denied, file an internal appeal within 60 days, request a peer-to-peer review, then pursue Virginia's external review process through the State Corporation

How to Get Strensiq (Asfotase Alfa) Covered by Humana in Virginia: PA Forms, Appeals, and Approval Strategy

Answer Box: Getting Strensiq Covered by Humana in Virginia Strensiq (asfotase alfa) requires prior authorization from Humana for pediatric-onset hypophosphatasia (HPP). The fastest path: 1) Confirm genetic testing shows pathogenic ALPL mutation, 2) Document persistently low age-adjusted alkaline phosphatase levels, 3) Submit PA request through Humana's provider portal

Get Crysvita (Burosumab) Covered by Cigna in Virginia: Complete Guide to Prior Authorization, Appeals, and State External Review

Answer Box: Getting Crysvita (Burosumab) Covered by Cigna in Virginia Cigna requires prior authorization for Crysvita (burosumab) with genetic confirmation of X-linked hypophosphatemia (XLH), clinical documentation, and serum phosphorus monitoring. The fastest path to approval involves three steps: (1) Complete genetic testing for XLH through the free Kyowa Kirin/Invitae